In a filing, 4D Molecular Therapeutics Inc revealed its Chief Legal Officer Bizily Scott unloaded Company’s shares for reported $45045.0 on Apr 16 ’24. In the deal valued at $25.74 per share,1,750 shares were sold. As a result of this transaction, Bizily Scott now holds 1,737 shares worth roughly $46551.6.
Then, Bizily Scott sold 8,153 shares, generating $259,102 in total proceeds. Upon selling the shares at $31.78, the Chief Legal Officer now owns 1,737 shares.
Before that, Bizily Scott sold 5,833 shares. 4D Molecular Therapeutics Inc shares valued at $204,410 were divested by the Chief Legal Officer at a price of $35.04 per share. As a result of the transaction, Bizily Scott now holds 1,737 shares, worth roughly $46551.6.
Barclays initiated its 4D Molecular Therapeutics Inc [FDMT] rating to an Overweight in a research note published on April 15, 2024; the price target was $459. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in mid April with a ‘”an Overweight”‘ rating. RBC Capital Mkts started covering the stock on October 26, 2023. It rated FDMT as “an Outperform”.
Price Performance Review of FDMT
On Tuesday, 4D Molecular Therapeutics Inc [NASDAQ:FDMT] saw its stock jump 0.15% to $26.80. Over the last five days, the stock has gained 11.99%. 4D Molecular Therapeutics Inc shares have risen nearly 32.28% since the year began. Nevertheless, the stocks have risen 58.21% over the past one year. While a 52-week high of $36.25 was reached on 03/27/24, a 52-week low of $9.44 was recorded on 01/19/24. SMA at 50 days reached $28.29, while 200 days put it at $19.44. A total of 0.33 million shares were traded, compared to the trading of 0.32 million shares in the previous session.
Levels Of Support And Resistance For FDMT Stock
The 24-hour chart illustrates a support level at 26.34, which if violated will result in even more drops to 25.89. On the upside, there is a resistance level at 27.17. A further resistance level may holdings at 27.55. The Relative Strength Index (RSI) on the 14-day chart is 51.91, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.49, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 20.43%. Stochastics %K at 76.56% indicates the stock is a holding.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $32 price target.
